OARSI/OMERACT Initiative to Define States of Severity and Indication for Joint Replacement in Hip and Knee Osteoarthritis. An OMERACT 10 Special Interest Group
Laure Gossec, Simon Paternotte, Clifton O Bingham, Daniel O Clegg, Philippe Coste, Philip G Conaghan, Aileen M Davis, Giampaolo Giacovelli, Klaus-Peter Gunther, Gillian Hawker, Marc C Hochberg, Joanne M Jordan, Jeffrey N Katz, Margreet Kloppenburg, Arturo Lanzarotti, Keith Lim, L Stefan Lohmander, Nizar N Mahomed, Jean Francis Maillefert, Rebecca L Manno Show all
The Journal of Rheumatology | J RHEUMATOL PUBL CO | Published : 2011
Awarded by National Institutes of Health (NIH)
Supported by unrestricted grants from OARSI and OMERACT and pharmaceutical companies Pfizer, Expansciences, Novartis, Negma Lerads, Rottapharm-Madaus, Fidia, and Pierre Fabre Sante Laboratories. Procter and Gamble Pharmaceuticals provided unrestricted access to placebo data from the KOSTAR study and an unrestricted grant to COB. LSL was supported by the Swedish Research Council; JAS was supported by the National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research). MSA holds a K24 award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and is partially supported by the Agency for Healthcare Research and Quality through finding of the Houston Center for Education and Research on Therapeutics (CERT). RLM is supported by NIH Training Grant T32 AR48522-06. P. Caste is an employee of Expanscience; A. Lanzaroni and E. Tajana-Messi are employees of IBSA; L.C. Rovati and G. Giacovelli are employees of Rottapharm-Madaus; COB served as a consultant and investigator for Procter and Gamble Pharmaceuticals, Novartis, and Merck and received an unrestricted grant from P&G Pharmaceuticals; LM has received a speaker honorarium and travel grant from Servier. JAS has received speaker honoraria from Abbott; research and travel grants from Allergan, Takeda, Savient, Wyeth and Amgen; and consultant fees from Savient and URL pharmaceuticals.